Fresh financial results from AstraZeneca show that a continued strong demand for cancer treatment drugs has driven steady results for the company.
The latest earnings report, released earlier this week, saw profit growth for 2026 expected to remain steady, if oncology demand stays high.
AstraZeneca, the biggest drug maker in Britain, has lofty goals to achieve by 2030, including US$80 billion in annual sales
"We have a lot of reason to believe we are very much on track to deliver our 2030 ambition," said CEO Pascal Soriot, who has served in the role since 2012.
The U.S and Chinese markets are a key target for AstraZeneca, with a US$50 billion manufacturing deal struck with the States last year and an announcement just last month that the company plans to invest $15 billion into China, its second biggest market, up to 2030.
This week's earnings report saw that oncology products made up 44% of revenue, and the U.S market was responsible for 43% of revenue when broken down by region.
